Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Lapaquistat acetate and rosuvastatin
Drug: Rosuvastatin

First Posted Date: 2005-11-07

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 415

Registration Number: NCT00249912

Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.

Phase 3

Completed

Conditions: Chronic Insomnia

Interventions: Drug: Placebo
Drug: Ramelteon

First Posted Date: 2005-11-01

Last Posted Date: 2010-06-03

Lead Sponsor: Takeda

Target Recruit Count: 451

Registration Number: NCT00247390

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

Phase 4

Completed

Conditions: Gastroesophageal Reflux

First Posted Date: 2005-11-01

Last Posted Date: 2012-05-07

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT00246909

Locations: 🇺🇸
Altana Pharma/Nycomed, Milwaukee, Wisconsin, United States

TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN)

Phase 3

Completed

Conditions: Surgical Resection of Superficial Renal Tumour

First Posted Date: 2005-10-18

Last Posted Date: 2012-08-03

Lead Sponsor: Takeda

Target Recruit Count: 170

Registration Number: NCT00241163

Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia

Phase 3

Completed

Conditions: Balance

Interventions: Drug: Placebo
Drug: Ramelteon
Drug: Zopiclone

First Posted Date: 2005-10-12

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 275

Registration Number: NCT00237497

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

Phase 2

Completed

Conditions: Diabetic Neuropathies

Interventions: Drug: TAK-128
Drug: Placebo

First Posted Date: 2005-09-29

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 343

Registration Number: NCT00229437

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Glimepiride
Drug: Pioglitazone

First Posted Date: 2005-09-23

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 547

Registration Number: NCT00225277

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Pioglitazone
Drug: Glimepiride

First Posted Date: 2005-09-23

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 458

Registration Number: NCT00225264

A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

Phase 1

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Lansoprazole

First Posted Date: 2005-09-22

Last Posted Date: 2010-07-22

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT00220818

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Placebo
Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2005-09-15

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 1072

Registration Number: NCT00174915

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy